300347 泰格医药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额408,6191,097,0021,150,4381,357,5011,423,796
投资活动产生之现金流量净额45,890(4,739,122)(1,534,225)(2,789,366)(2,782,684)
筹资活动产生之现金流量净额(826,950)(1,702,410)(7,806)809,254(163,093)
汇率变动对现金及现金等价物的影响14,360(6,917)8,79326,934(59,565)
现金及现金等价物净增加/(减少)(358,081)(5,351,448)(382,800)(595,677)(1,581,546)
期初现金及现金等价物余额2,048,4947,399,9417,782,7418,378,4189,959,963
期末现金及现金等价物余额1,690,4132,048,4947,399,9417,782,7418,378,418